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1. Introduction 
Despite significant advances in supportive care, infectious complications continue to be a 
significant cause of morbidity and mortality in leukemia patients. The implementation of 
empiric antibiotic therapy in febrile neutropenia led to dramatic reduction in mortality 
and was hailed as a turning point in cancer treatment (1). Nonetheless, the development 
of more effective and dose intensive salvage chemotherapy regimens, incorporation of 
monoclonal antibodies, use of consolidation and maintenance strategies,  and increased 
use of indwelling venous catheters have increased susceptibility to infections and changed 
the spectrum of infections in patients with leukemia (1). Specifically, multidrug resistant 
organisms, as well as those previously considered innocuous have emerged. Even under 
the optimal circumstances i.e. timely diagnosis and implementation of appropriate 
therapy, infections in leukemia remain a therapeutic challenge. Furthermore, delayed 
recognition and/or poor implementation of the appropriate treatment strategy can lead to 
significant morbidity and mortality while potentially increasing the economic burden 
associated with the infections seen in this immunocompromised population. Therefore, it 
is imperative that clinicians caring for this vulnerable group of patients have a thorough 
understanding of the infectious complications associated with leukemia and leukemia 
directed therapy.  
This chapter includes a discussion of 
a. Basic concepts and definitions; 
b. Pathogenesis of infections in acute and chronic leukemia; 
c. Spectrum of infections, with a focus on new and emerging infections;  
d. Risk of certain infections associated with specific chemotherapy medications; 
e. Clinical evaluation of suspected infection; 
f. Treatment strategies, including empiric therapy and management of documented 
infection; 
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g. Role of prophylactic and preventive measures, in patients with acute and chronic 
leukemia;  
h. Economic impact and outcomes. 
1.1. Basic concepts and definitions 
Fever in a neutropenic patient is usually defined as a single temperature >38.3ºC (101ºF), or a 
sustained temperature >38ºC (100.4ºF) for more than one hour (2). 
Neutropenia is defined as an absolute neutrophil count (ANC) of less than 500cells/ microL 
whereas ANC less than 100 cells /microL is indicative of profound neutropenia (2).  
Innate immunity refers to the body's natural resistance. It provides the first line of defense 
against a variety of pathogens. Innate immunity is not disease or pathogen specific and is 
composed of anatomic (skin and mucous membranes), physiologic (body temperature, 
gastric pH), and chemical (complement system) mediators, lysozyme and toll like receptors, 
phagocytic, and inflammatory aspects (3).  
Adaptive immunity mediated by lymphocytes is a slower but highly specific response to 
antigen stimulation (3). B and T lymphocytes receive whole or partially processed antigens 
from antigen presenting cells from lymphoid tissue (lymph nodes and the spleen). These 
cells multiply at the site of infection to evoke a highly targeted antigenic response. Cytotoxic 
T (CD8+) lymphocytes spearhead the body’s defense against intracellular pathogens. Helper 
T( CD4+) lymphocytes play a supportive role in providing necessary signals to CD8+ T 
lymphocytes that help not just in the primary response to infection, but also in the 
generation of memory CD8+ T cells and recruitment of CD8+ cells at the site of infection (4). 
B lymphocytes secrete antibodies, process and present antigens and transform into a pool of 
memory B cells for future defense (4). This capacity to retain immunologic memory is the 
distinguishing feature of adaptive immunity. Studies in murine models have demonstrated 
that NK cells, not just B and T lymphocytes possess the capacity to transform into memory 
cells (5). Immunologists have customarily considered Natural killer (NK) cells as a part of 
the innate system due to their ability to respond rapidly albeit non- specifically to infection 
(5). However unlike B and T lymphocytes that can generate responses to an unlimited range 
of antigen-specific receptors, NK cells can generate antigen specific responses limited to a 
population but not at an individual level. These cells are thought to represent a 
developmental transition between the innate and adaptive immune systems (5). 
1.2. Pathogenesis of infections in leukemia 
The acute leukemias are characterized by the rapid proliferation of immature progenitor 
cells and include acute myelogenous leukemia (AML) and acute lymphoblastic leukemia 
(ALL). Chronic leukemias typically run a more indolent course. This group includes chronic 
myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL) and hairy cell leukemia 
(HCL). The accumulation and slow proliferation of mature appearing but functionally 
incompetent leukocytes is the common underlying pathology in chronic leukemias. The 
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clinical presentations of infections are determined by a complex interplay between the 
pathogen and its virulence and the defense mechanisms of the host and the degree to which 
this is impaired. 
Disease specific factors associated with host immune response 
Studies in the early twentieth century led to a gradual shift in our understanding of the 
pathogenesis of infections. It became apparent that infections were not solely determined by 
the inherent virulence of the organism but also the susceptibility of the host (6).  
In acute leukemia normal hematopoiesis is replaced by abnormal maturation and 
dysregulated proliferation of leukocytes (7). Coupled with significant bone marrow 
infiltration, this leads to decreased production of normal granulocytes resulting in 
neutropenia and impaired granulocyte function. Additionally, the presence of a large 
number of immature myeloid cells can inhibit antigen specific T cell response (8) Therefore, 
newly diagnosed leukemia patients often present with concurrent infections (7). Treatment 
with standard induction regimens results in prolonged neutropenia that can last weeks, 
rendering the host highly susceptible to bacterial and fungal infections (7). Furthermore, 
polymorphonuclear leucocyte function may be adversely affected by several 
chemotherapeutic medications such as high dose glucocorticoids, vincristine, vinblastine, 
carmustine, cyclophosphamide and 6- mercaptopurine (9). The risk of severe infections is 
not uniform among these patients and is related to the degree and duration of neutropenia 
(7) with the risk of developing more serious infections increasing with prolonged 
neutropenia (10) (11), the use of salvage chemotherapy, and previous antibiotic exposures 
(12).  In acute leukemia patients, the risk of infection does not fully abate after achieving 
remission as patients can have prolonged defects in humoral immunity (13).  This risk 
increases further with relapse of disease (14). 
In addition, chemotherapy-induced mucosal disruption of the oropharynx and 
gastrointestinal tract enables normal commensals to access the bloodstream and cause 
invasive disease (15). In the 1980s, the use of central lines became widespread and 
contributed to the increased incidence of blood stream and systemic infections with skin 
flora (15).  
Patients with CLL have defects in both humoral and cellular immunity as a result of their 
underlying malignancy, as well as therapy-related immune suppression from 
chemotherapeutics such as alkylating agents, purine analogues and monoclonal antibodies 
(16). Although these drugs have dramatically improved CLL outcomes, the predisposition 
to serious infections can result in significant morbidity - 80% of CLL patients will have a 
significant infection over the course of their disease, with up to 60% of people dying from 
infection (17). 
B cell defects in patients with CLL can lead to hypogammaglobulinemia in the majority of 
patients (up to 70% within seven years of diagnosis) (18). Deficiencies can be seen in all 
three classes of immunoglobulins -IgG, A and M and is worse with advanced disease stage 
(19, 20).  Severity and incidence of infections particularly respiratory infections correlated 
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with low levels of serum IgG (19) as well as  IgA (21,22). Decreased levels of opsonizing 
antibodies typically result in infections due to encapsulated organisms such as 
Streptococcus pneumoniae, Haemophilus influenza, and Neisseria meningitides (17). These 
patients also tend to respond poorly to vaccination (23). Impaired function of NK cells (lack 
of azurophilic granules that are necessary for normal killing activity (24)), neutrophils 
(reduced chemotaxis and migration) and monocytes and macrophage system have also been 
noted.  T cells show a number of defects including abnormalities in gene expression and 
CD30 response, decreased CD4 to CD8 ratio (25), impaired Th2 polarization, and reversible 
acquired CD40 ligand deficiency (26))  all of which prevent T cells from initiating or 
maintaining and completing an immune response(18). Furthermore, patients can develop 
disease or therapy related neutropenia. These multiple immune defects predispose patients 
to bacterial, fungal, and viral infections.  
Although the advent of improved diagnostics and more effective therapies have largely 
obviated the need for splenectomy across a number of hematologic malignancies, it may be 
performed for diagnostic reasons or in the setting of symptomatic splenomegaly, refractory 
autoimmune hemolytic anemia or thrombocytopenia (27,28). The spleen is a large mass of 
lymphoid tissue pivotal in filtering blood borne pathogens. It is also an antibody producing 
organ (29) and plays a role in the activation of alternative complement pathway which may 
be abnormal in those with anatomic or functional asplenia (30). Splenectomy therefore 
further predisposes this already at risk population serious infections including rapidly fatal 
infections with encapsulated organisms (see above), babesiosis, and capnocytophaga 
canimorsus (31-34).  
HCL is an uncommon adult B-cell lymphoid leukemia that typically runs an indolent course 
and like CLL, many patients do not require immediate treatment (35). Clinical features 
include pancytopenia, splenomegaly (which may be complicated by rupture or infarction), 
and absolute monocytopenia (35). Infections remain a significant problem, presumably due 
to neutropenia and monocytopenia (36), and have been found to be prognostic. For example, 
survival at 4 years from diagnosis is markedly lower in individuals who have had infections 
as opposed to those who have not (49% versus 92%, p=0.0012)(36).  
Age and malnutrition 
Other factors that have been evaluated in the pathogenesis of infections in patients with leukemia 
include age and nutritional deficiencies. Fanci and colleagues compared the effect of age on the 
incidence of nosocomial infections in patients with acute leukemia older than 60 yrs compared to 
younger patients (37). The authors concluded that the risk of infection was no different in the 
study groups despite the added decline in immune function with age. However these results 
needed to be evaluated with caution as they were likely confounded by the fact that elderly 
patients with relapsed/ refractory disease were generally treated with less aggressive treatment 
regimens (37) which inherently may be associated with less infectious risk. 
Nutritional deficiencies may also adversely affect the ability of normal tissue to withstand 
toxicity from chemotherapy resulting in need for discontinuation or dose reduction of 
chemotherapy (38); however, its impact on infections in leukemia is not well defined.  
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Key points 
 In acute leukemia there are quantitative and qualitative defects in leukocyte function. 
 The risk of infections in neutropenic fever is determined by the severity and duration of 
neutropenia. 
 Disruption of mucosal lining due to toxic effects of chemotherapeutic drugs and the use 
of central venous catheters contribute to the risk of infection due to commensal 
organisms. 
 In CLL both humoral and cellular immunity are impaired leading to a predilection to 
infection with encapsulated and intracellular organisms respectively. 
 Patients with HCL are also at increased risk for infections which may be associated with 
worse outcomes. 
1.3. Spectrum of infections in leukemia patients 
Febrile neutropenia 
The most common bacterial pathogen in the 1960s in neutropenic patients was 
Staphylococcus aureus (10,39). However, presumably due to the widespread use of 
methicillin, fatal staphylococcal infection rates dropped from 23.5% in 1954 to 3.1% in 1963 
according to a ten year review of National Cancer Institute data (40).  This success was 
dampened in the late 1960s and early 1970s by the emergence of aerobic gram-negative 
bacilli such as Klebsiella pneumonia, enterobacter , E. coli, Pseudomonas and other enteric 
organisms such as enterococci and anerobes(39). Cephalothin, a first-generation 
cephalosporin, led to improved outcomes with these infections. This period marked the 
emergence of Pseudomonas aeruginosa as a major pathogen associated with high mortality 
rates in this population (39). Although polymyxin and gentamicin were available as 
monotherapies to treat Pseudomonas bacteremia, the use of the  first anti-pseudomonal 
carboxy penicillin carbenicillin, in combination with gentamicin,  significantly reduced 
mortality from 60% in the 1960s to 10-30% in the 1980s (39).  
In the 1990s, given their oral route of administration, broad spectrum of activity including 
against gram negatives, good bioavailability, and general low toxicity, prophylactic 
fluoroquinolone use became widespread. In addition, emerging resistance patterns resulted 
in an increased reliance on third generation cephalosporins for prophylaxis, empiric therapy 
for neutropenic fever, or treatment of gram negative infections.  These developments, along 
with the increased use of implantable venous catheters, shifted the spectrum of infections 
back towards gram positive organisms such as staphylococcus and streptococcus species 
(41). Use of H2 antagonists and other antacids in conjunction with fluoroquinolones have 
also been implicated as a potential contributing factor to this shift (41,42). 
Bloodstream infections (BSI) are commonly associated with mucositis, cellulitis, pneumonia, 
neutropenic enterocolitis, invasive fungal disease and central venous catheters (43,44) . The 
clinical presentations of BSI may vary from bacteremia to fulminant shock.  In a survey of 49 
hospitals between 1995 and 2001, the frequency of gram positive bloodstream infections 
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increased from 62% in 1995 to 76% in 2001(45). The source of BSI was not identified in 52% 
of cases in this study.  One hospital based study reported the re-emergence of gram negative 
organisms in primary nosocomial BSI (46). Interestingly, a seasonal increase in the incidence 
of gram negative BSI, particularly Acinetobacter, and to a lesser degree E.coli has recently 
been noted, stressing a need for greater vigilance during summer months (47).  The 
epidemiology of BSI is included in Table 1. Coagulase negative staphylococci, 
Staphylococcus aureus, Viridans streptococci, and gram negatives are the most likely 
pathogens.  Although candida is well known as a cause of catheter related blood stream 
infection, atypical catheter related infections from mycobacteria, nocardia, and 
Tsukamurella  have been reported (48-52). 
It should be emphasized that gram-negative organisms continue to dominate the scene as 
the most frequent pathogens causing infections in febrile neutropenic patients. Apart from 
BSI, other sites of infection include the respiratory tract (pneumonia, sinus), skin and soft 
tissue (mucositis and cellulitis), gastrointestinal (diarrhea , typhlitis, perirectal abscess, and 
enterocolitis) and genitourinary tract (UTI,) in order of frequency (53-55).  Neutropenic 
enterocolitis, notorious for its morbidity and mortality may be further complicated by 
polymicrobial BSI due to aerobic gram negative bacilli and anerobes such as Clostridium 
septicum (56).  The gastrointestinal tract (including the oral cavity) is often the site of origin 
of polymicrobial BSI. Elting and colleagues delineated factors associated with the poor 
response to treatment in a large study of polymicrobial infections in cancer patients. These 
included persistent neutropenia (25%), pneumonia (19%), and bloodstream infection caused 
by multiple gram-negative organisms (49%) (57) . 
 
Clinical syndromes Pathogens/ Risk factors
Upper gastrointestinal -Gingivostomatitis 
and periodontal lesions 
Streptococci, gram negatives, herpes simplex, candida 
and uncommon bacteria like stomatococcus and 
aerococcus 
Gastrointestinal infections- Typhlitis, 
neutropenic enterocolitis, perirectal abscess 
Gram negatives and anerobes, C-diff.  
Lower respiratory tract infections-
Pneumonia (64)(65) 
 Gram negative bacilli, pneumococci, moulds, virus e.g 
CMV 
Blood stream infections 
(45,66). 
Coagulase negative staphylococcus (the most common 
isolate), S. aureus, E.coli and P.aeruginosa  
Polymicrobial infections 
(67) 
Gram-positive, anaerobic, or fungal , often seen with 
concurrent presence of a gram-negative bacillus.   
Skin and soft tissue -cellulitis and folliculitis Streptococci, staphylococci, anaerobes and gram 
negatives 
Table 1. Sites of infection in neutropenic patients 
Clostridium difficile associated diarrhea is common is patients with acute leukemia 
especially AML (58,59). It accounts for approximately one third of episodes of diarrhea and 
is more common with older age, number and duration of antibiotics and prolonged 
neutropenia prior to onset of diarrhea (59). Fluoroquinolone use has been implicated in the 
increased incidence of resistant Clostridium difficile (C-diff) infections (60). Toxin negative 
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Clostridium infections which have been described in up to 10% of patients, are particularly 
problematic, and require endoscopic studies for diagnosis (61). C-Diff  therapy  consists of 
metronidazole or, in severe cases, oral vancomycin (62), which has become the initial agent 
of choice at some institutions (63) due to increasing emergence of metronidazole resistance. 
Fidaxomicin is a new macrocyclic antibiotic has been shown to have clinical cure rates 
similar to vancomycin but superior in terms of lower recurrence rates (62). Table 1 
summarizes the clinical syndromes, sites of infection and associated pathogens in 
neutropenic patients. 
Resistant bacterial pathogens 
Patients with leukemia are predisposed to infections and thus exposed to multiple 
antibiotics during the course of their therapy. The emergence of resistant organisms in this 
cohort of patients can be catastrophic.  
1. Methicillin resistant Staphylococcus aureus (MRSA):  accounts for 20-30% of 
nosocomial BSI and can lead to metastatic complications such as deep tissue and focal 
abscesses (e.g epidural, splenic), endocarditis and septic arthritis. MRSA is resistant to 
penicillin, cephalosporins and quinolones.  
2. Vancomycin resistant staphylococci (VRSA): has become a growing concern no doubt 
due to the widespread use of vancomycin. Although linezolid and daptomycin can be 
used, these isolates may be less sensitive to these agents as well (68). 
3. Vancomycin sensitive and vancomycin resistant enterococci (VRE): Risk factors include 
neutropenia, fluoroquinolone use, and previous treatment with vancomycin. E. 
faecium, which is often vancomycin resistant, has now surpassed E. faecealis as the 
predominant organism and is associated with a two-fold risk of higher mortality-in 
excess of 70% in the setting of neutropenia. In an attempt to decrease this risk, some 
centers have begun to isolate immunosuppressed VRE-colonized patients and employ 
barrier precautions (i.e. gowns, gloves); however, it is not yet clear if this approach 
impacts the outcomes of VRE infections. Linezolid and daptomycin are reasonable 
therapeutic options for the treatment of VRE infection. (41,69,70). 
4. Multidrug resistant gram negative organisms have become especially problematic 
presumably due to the widespread use of antibiotics in this population. Extended 
spectrum beta-lactamase producing bacteria, such as Klebsiella and E coli, are resistant 
to fluoroquinolones, cephalosporins and penicillins (71). The carbapenams are usually 
effective in treatment. However in cases of carbapenamase producing Klebsiella, 
colistin can be used. Multidrug resistant pseudomonas requires colistin or polymixin B 
therapy (72). 
Fungal infections 
Invasive fungal infections (IFI) have been implicated as a complication in leukemia since the 
1940s (10) and continue to be a major cause of morbidity and mortality in leukemia patients. 
Autopsy studies identified IFI as a cause of persistent fever and subsequent demise in 
neutropenic patients unresponsive to broad spectrum antibiotic therapy (10). The use of 
empiric antifungal therapy led to improved survival; however, it was often difficult to 
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confirm a diagnosis of IFI. This in turn often led to overtreatment with antifungal 
medications and thereby significant treatment related costs and morbidity (73). Table 2 
outlines the spectrum of fungal infections in neutropenic seen in leukemia patients. 
Although candidiasis and aspergillosis continue to be the predominant pathogens, 
additional fungi have emerged (Table 2). IFI should be suspected in the setting of persistent 
fever despite broad spectrum antibiotics.  
 
Fungal Pathogen Clinical features
Candida spp. 
(74) 
Most common IFI infection. Severe immune suppression, broad spectrum 
antibiotics and central venous catheters are risk factors. Clinical presentation can 
range from BSI, gastrointestinal candidiasis and acute disseminated candidiasis. 
Trichosporon spp.
(75)(76) 
 
 
Unusual fungal infection more often diagnosed per case reports in AML patients. 
It presents similar to candidemia and may also be associated with skin, kidney and 
lung findings if disseminated. 
Cryptococcus(76) Rare in leukemia, likely due to widespread prophylaxis with fluconazole, but if 
seen, occurs most often in AML, CLL and CML. Underlying severe T cell 
depletion, diabetes mellitus and use of steroids are added risk factors. Lung and 
nervous system  often affected. 
Aspergillus 
sp(77)(78)(74)(79) 
Lungs, sinus and CNS infections often seen. Risk factors include prolonged 
neutropenia especially AML and steroid use (non neutropenic patients). Lung 
infections can present as fever, cough, pleuritic chest pain and massive pulmonary 
hemorrhage. Nodular pneumonia and CT finding of a nodule with a halo sign are 
characteristic. Serum galactomannan (GM) assay used with variable success in 
screening and diagnosis. Bronchoalveolar lavage (BAL) galactomannan optical 
density > 3.0 had 100% positive predictive value and less than 0.5 had high 
negative predictive value. False positive GM may be seen with concomitant 
administration of piperacillin/tazobactam, severe gastrointestinal mucosal 
disruption, and pneumocystis (PJP). 
Zygomycetes 
(80-82) 
Presents similar to aspergillus infections. Pathogenesis involves vascular invasion 
and tissue infarction manifesting as pulmonary, rhinocerebral and cutaneous 
infections.  May progress rapidly; mortality in excess of 80% in disseminated 
disease.
Scedosporium 
 
(76)(83) 
Can cause skin or pulmonary involvement. Associated with high mortality. 
Surgical drainage of fluid collections in skin, joint or soft tissue and systemic 
treatment are the cornerstones of therapy. 
Endemic mycoses 
(84-88) 
Reactivation of endemic fungal infections such as histoplasmosis, blastomycosis 
and coccidiomycosis can occur in the setting of immune suppression and can occur 
several years after leaving the region of original infection. Histoplasmosis may 
present in a disseminated fashion.  
Table 2. Fungal infections in leukemia 
Key points 
 In neutropenic patients gram negative organisms remain the most frequent pathogens 
at sites other than blood stream infections. 
 Gram positive organisms particularly oral commensals emerged as the leading cause of 
bloodstream infections in the 1980s. 
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 A number of factors such as the increased use of antibiotic prophylaxis and 
indwelling venous catheters have altered the spectrum of infections in leukemia 
patients. 
 Clostridium Difficile infection has emerged as a major cause of morbidity in leukemia 
patients. 
 Persistent fever after 4-7 days of broad spectrum antibiotics may indicate occult IFI. 
Non- neutropenic patients 
Among non-neutropenic patients with leukemia, a number of bacterial, viral, fungal and 
other opportunistic infections have been described. With the introduction of newer 
immunosuppressive or more aggressive therapies such as purine analogues, multiagent 
combination chemotherapy, monoclonal antibodies and steroids, the increased frequency of 
more atypical infections. With the introduction of newer immunsosuppressive or more 
aggressive therapies more atypical infections, such as CMV, Pneumocystis jirovecci 
pneumonia (PJP), liseria meningitis, and IFI have been seen highlighting the need for 
deliberation when selecting the the appropriate treatment regimen. Individuals at greatest 
risk of infection include those who have active disease, have undergone multiple previous 
treatment regimens, and longer disease duration (18).  
Among the infections in patients with both acute and chronic leukemia, listeriosis is notable 
for its predilection for the central nervous system (90, 91). Listeria is a gram positive bacillus 
that gains entry into the blood stream via the gastrointestinal tract (90) . Listeriosis can 
present with bacteremia or with CNS involvement (meningitis (92), meningoencephalitis or 
cerebritis). Steroid therapy and nucleoside analogs such as fludarabine, which deplete T 
cells, are treatment associated risk factors (90). Ampicillin is the drug of choice, although 
vancomycin, carbapenams, fluoroquinolones and linezolid have good in vitro activity. 
Among viral infections, herpes virus reactivation is relatively common, with localized 
Herpes zoster reported more often than (93) disseminated infections (94-96). In addition, 
Epstein-Barr virus (EBV) reactivation is important and has been implicated in Richter’s 
transformation (97). 
Tuberculosis is seen in CLL more frequently than in other hematological malignancies (98). 
This is especially true for patients treated with fludarabine and the anti-CD52 monoclonal 
antibody alemtuzumab (as described in section C) (98). Atypical mycobacterial (99) infection 
in chronic leukemia is linked to a high mortality especially if disseminated (99-101). Clinical 
sites include skin (102,103), lung and multifocal osteomyelitis (104), but occasionally there 
may be no signs and symptoms other than fever.  Bone marrow culture has a high 
diagnostic yield.  
PJP can rapidly progress from fever and dyspnea to acute respiratory failure in a few hours 
(16). Parasitic infections such as toxoplasmosis and strongyloidiasis are rare in leukemic 
patients but have been described.  For example, cerebral toxoplasmosis has been linked to 
patients with fludarabine refractory CLL with profound CD4 lymphopenia (105) and is 
associated with high mortality. 
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Key points 
 Non-neutropenic patients with leukemia are susceptible to a host of bacterial, viral, IFI 
and other opportunistic infections. 
 Patients with CLL and HCL who have been treated with newer immunosuppressive 
therapies remain profoundly lymphopenic several months after cessation of therapy 
and at risk for various opportunistic infections. 
 Factors associated with increased risk of infection include duration of disease, T cell 
depletion, active disease and individuals who have undergone multiple prior therapies. 
Other emerging pathogens  
Unless the treating physician is aware of the pathogenic potential of bacteria widely 
believed to be harmless in the immunocompetent host, positive culture results may be 
dismissed as insignificant or as a contaminant. 
 Fusarium is a mold that can cause rapidly fatal infections. Skin involvement is common 
and blood cultures are often positive. High dose liposomal amphotericin is the 
treatment of choice (106-110). 
 Corynebacterium (e.g Corynebacterium pseudodiphtheriticum , Corynebacterium jeikeium) 
Corynebacterium is a gram positive bacillus that may present clinically as catheter related 
infections, pneumonia, endocarditis, urinary infections, keratitis and sepsis (111). 
Immunoglobulin deficiency in CLL is a predisposing factor (112). Mortality in the 
neutropenic host can be as high as 34% (111). Corynebacterium jeikeium is resistant to 
multiple antibiotics and vancomycin is the recommended antibiotic of choice (113). 
 Stenotrophomonas maltophilia is a gram negative bacillus that normally resides in the oral 
mucosa. Patients with prolonged neutropenia and T cell defects may present with life 
threatening syndromes of hemorrhagic pneumonia and ecthyma gangrenosum. 
Trimethoprim-sulfamethoxazole and fluoroquinolone-based multidrug combination regimens are 
used as first line treatment (114-117). 
 Bacillus cereus: A gram-positive rod that is typically associated with foodborne illness in 
the immunocompetent host. Patients can present with pneumonia, necrotizing gastritis, 
septic shock, multiorgan failure, disseminated intravascular coagulation, brain abscess, 
critical illness polyneuropathy and myopathy. Leukemia patients, particularly ALL 
patients, are more vulnerable. Risk factors that predict poor outcomes include severe 
neutropenia, presence of central venous catheters and CNS symptoms (118-122). 
 Lactobacillus is a gram positive bacillus that may cause infection in the neutropenic 
patient. It presents usually as sepsis or pneumonia. Importantly, vancomycin has poor 
activity against Lactobacillus, and treatment with penicillin or related compounds is 
recommended instead (123). 
1.4. Risk of infections due to specific chemotherapy agents 
Alkylating agents and Anthracyclines 
Anthracyclines (idarubicin, daunorubicin, and doxorubicin) are unique among 
chemotherapeutic drugs in that they induce apoptosis of hematopoietic cell lines (124) in the 
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G0-G1 phases of the cell cycle. They can deplete the peripheral T-cell pool and cause 
neutropenia secondary to myelosuppresion.(124) which can result in bacterial infections and 
IFI. However the incidence of gram negative infections and ≥ grade3 /4 infections (i.e. 
requiring IV antibiotics) may be reduced by the use of pegylated liposomal doxorubicin 
possibly due to reduced overall myelotoxicity (125). 
Alkylating agents (e.g chlorambucil, cyclophosphamide, melphalan, bendamustine etc) 
cause DNA damage and prevent DNA repair activity both in normal and leukemic cells 
(126). Pyogenic infections due to Staphylococcus aureus, Streptococcus pneumoniae, 
Haemophilus influenza, Klebsiella and E. coli account for the vast majority of infections in 
patients treated with alkylating agents (17). These frequently involve the respiratory tract; 
however, infections of the urinary tract, skin and soft tissue can also occur. BSI are more 
likely to be seen in neutropenic patients. Candidiasis and aspergillosis occur in patients with 
prolonged neutropenia or who are treated concomitantly with high-dose steroids, 
prolonged antibiotic therapy, combination chemotherapy. Nocardia, listeria, mycobacteria 
and PJP can occur but are uncommon in CLL patients treated with alkylating agents alone 
(17).  
Purine and Pyrimidine analogues 
Purine nucleosides cladribine, fludarabine and pentostatin have been extensively used in 
CLL, HCL and other indolent B cell lymphoproliferative disorders. The risk of infections with 
these agents is related to both quantitative and qualitative T cell defects. Their use can result 
in prolonged suppression of all T cells especially CD4 cells, which can last up to 11-40 months 
after completion of treatment (127) (17). Consequently, as noted previously, the spectrum of 
infections broadens to include organisms such as Listeria, Nocardia, and mycobacteria. 
Disseminated candidiasis and aspergillosis are well recognized offenders. Concurrent 
treatment with steroids increases the likelihood of pneumocystis infections (93). Viral 
infections are common, especially varicella zoster virus (VZV) infection, which may be 
complicated by a high incidence of post-herpetic neuralgia. Reactivation of hepatitis B, 
adenovirus and cytomegalovirus (CMV) infections have been described (17). Cladribine has 
been used in CLL and HCL and can also cause prolonged suppression of CD4 cells which 
may recover at a a median of 40 months after therapy with CD8 cells returning to normal at 3 
months (127).  Purine nucleosides are stem cell toxic (128) and thus, may induce severe bone 
marrow suppression. The incidence of severe neutropenia has been reported as varying from 
16-42% (129,130) and may persist for many months after completion of therapy. However, 
documented infections-where a pathogen is identified- are less common at 7-13%(129,130). 
Clofarabine is a second-generation nucleoside analog approved for the treatment of 
childhood ALL. It has been studied alone or in combination with cytarabine or idarubcin in 
adult patients with relapsed and/or refractory acute leukemia (131,132).  The risk of 
myelosuppression and neutropenic fever is very high. In one study, Grade 4 neutropenia 
(ANC < 500) occurred in all patients and 38% developed a bacterial infection (12).  
Of the pyrimidine analogs, cytarabine (cytosine arabinoside, Ara-C) is widely used in the 
treatment of both AML and ALL. Mayer and colleagues presented the results of using low 
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(100 mg/m2), intermediate (400 mg/m2) and high dose cytosine arabinoside (3 gm/m2) for 
post remission chemotherapy in adult patients with AML. Myelosuppression resulted in ≥ 
Grade 3 neutropenic fever -significant to require hospital admission- in 71% (133) of patients 
in the high dose arm. Treatment-related deaths during remission, attributable to infections 
occurred in 1, 6 and 5% percent of the patients assigned to the low, intermediate and high 
dose groups respectively (133). 
Corticosteroids  
Corticosteroids are synthetic analogs of hormones produced in the adrenal cortex and are 
frequently used in the management of leukemia patients, particularly those with lymphoid 
malignancies. Despite their widespread benefits, the risk of infections is well known. 
Steroids impair T cell and neutrophil function, may camouflage classic signs and symptoms 
of inflammation, and are an independent risk factor for serious opportunistic infections in 
patients receiving other immunosuppressive therapy such as induction chemotherapy, 
alkylating agents and nucleoside analogues (17) (89). 
A wide spectrum of bacterial, viral (CMV, HSV, VZV), fungal, tubercular and opportunistic 
infections have been reported in patients treated with chronic steroids (134,135). 
Infections associated with corticosteroids are dependent on the route of administration 
(parenteral worse risk than oral route), dose, and duration of therapy -daily dose greater 
than 10 mg per day or a cumulative dose of more than 700 mg- as evidenced by data from 71 
clinical trials (135). Unfortunately this analysis excluded trials in which patients were 
already on antiviral, antibacterial or antifungal prophylaxis, preventative practices common 
in this group of patients.  
Monoclonal antibodies  
Monoclonal antibodies have gained popularity for the treatment of various hematological 
malignancies. They potentially allow for more narrowly directed therapy for these diseases 
by targeting specific antigens expressed on the cell surface of malignant cells. However, 
normal hematopoetic cells express the target as well, resulting in off target effects. While a 
number immune conjugates, which incorporate antibody directed delivery of various toxins, 
have been developed, the majority of commercially available monoclonal antibodies rely on 
complement mediated and antibody mediated cytotoxicity against the malignant cells (136) 
which can disrupt adaptive immunity.   
Rituximab is directed against CD20, which is a cell surface antigen expressed on B cells. It 
has limited use in CLL as monotherapy in part due to the limited expression of CD20 on 
malignant B cells in CLL (137). However, it has been shown to significantly improve 
outcomes when added to other agents (138). Neutropenia that can be seen including late 
onset neutropenia occuring several weeks to months after treatment, is typically self-limited 
with no clinically significant risk of infections, and appears to be linked to B cell recovery 
(139). Rituximab has been associated with reactivation of hepatitis B infection, which may be 
severe enough to require urgent liver transplantation (140), as well as progressive multifocal 
leukoencephalopathy (PML), which is due to reactivation of JC virus (141,142).  
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Ofatumumab is a novel fully humanized anti-CD20 monoclonal antibody recently approved 
for the treatment of CLL refractory to alemtuzumab and fludarabine (148). In the pivotal 
study, Grade 5 (fatal) infections were seen in 10% (149) of patients with pneumonia being 
the most frequent cause of infection. In a similar study 8-12% of patients developed grade 3 
or 4 infections while receiving ofatumumab treatment (150) although the degree of 
additional immunosuppression mediated directly by ofatumumab is debatable as these 
patients were already severely immunosuppressed at the initation of therapy. Similar to 
rituximab, ofatumumab can cause neutropenia, however, the risk of grade 3 or 4 
neutropenia in this heavily pre-treated populations was significantly higher (42% grade 3, 
18% grade 4) (151).  
Alemtuzumab: Alemtuzumab is a humanized monoclonal antibody directed against CD52, a 
cell surface glycopeptide expressed on virtually all human lymphocytes, monocytes and 
macrophages, a small subset of granulocytes, but not on erythrocytes, platelets or bone 
marrow stem cells (137). Alemtuzumab is used in the treatment of CLL and T cell 
prolymphocytic leukemia. Given the near ubiquitous expression of CD52 on immune cells, 
treatment results in the loss of circulating T cells, leading to defective cell mediated 
immunity and neutropenia in approximately 1/3 of patients. As a result, CMV reactivation 
occurs in 15 to 25% of patients and is the most commonly observed opportunistic infection 
(137,143-145). Other infections include herpes simplex, varicella zoster, PJP, candidiasis, 
cryptococcosis, toxoplasmosis and mold infections(aspergillosis and mucormycosis) (17) It is 
recommended that all patients receiving alemtuzumab receive antiviral prophylaxis 
(acyclovir, valacyclovir or famciclovir). Although valganciclovir is effective in preventing 
CMV reactivation (146), it can suppress bone marrow function and current guidelines 
recommend weekly screening for CMV viremia using PCR, and pre- emptive treatment with 
ganciclovir or foscarnet when patients are symptomatic or show increase in viremia (144). In 
a Cancer and Leukemia Group (CALGB)  study by Lin et al (147) alemtuzumab was 
administered to patients who received induction therapy with fludarabine and rituximab. 
Improved complete response was noted, but event free survival did not improve due to 
serious infections (including listeria meningitis, CMV reactivation and PCP pneumonia) 
which occurred up to 7 months after completion of therapy (147). 
Tyrosine Kinase inhibitors 
Tyrosine kinase inhibitors (TKI) disrupt T-cell receptor mediated T-cell proliferation, 
activation and selective inhibition of memory CTL responses without interfering with 
primary T or B cell responses. Imatinib is the first agent in this class and has significantly 
improved the outcomes of CML patients (152).  In a study of 250 CML patients treated with 
imatinib the most frequently seen infections were pneumonia, herpes zoster reactivation 
and urinary tract infections. The incidence of opportunistic infections was low (153). 
Dasatinib is a multikinase inhibitor used for CML and ALL. It acts both as an antineoplastic 
and immunosuppressive agent at doses 140 mg or above. Grade 3 or 4 infections are more 
problematic in the accelerated phase compared to the chronic phase of the disease (89% 
versus 45%) (154) which is likely related to the underlying disease process. 
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Nilotinib 
Nilotinib is an orally bioavailable TKI with increased selectivity for bcr-abl relative to other 
targets such as Src family or c-kit kinases. This probably accounts for the high efficacy of 
nilotinib without severe myelosuppression (155). Although all tyrosine kinase inhibitors 
cause myelosuppression, nilotinib is associated with more garden variety types of 
infections. In a phase II trial involving 280 patients with CML in chronic phase, grade 3/4 
neutropenia  (ANC < 1000)  was noted in 29% of patients with a median duration of 15 days 
and need for dose interruptions or modifications in 10% of patients (155). 
Key points 
 Atypical infections are common in patients with CLL and HCL treated with monoclonal 
antibodies and purine nucleosides. 
 Alemtuzumab is particularly immunosuppressive and its use requires close monitoring 
for CMV reactivation as well as prophylaxis for PJP and fungal infections. 
 Concurrent use of steroids significantly increases the risk of infections.  
 Risk of severe infections may persist for months after cessation of therapy. 
 The risk of infections in patients with CML receiving TKIs is relatively low. 
1.5. Initial evaluation and risk stratification 
Neutropenic fever is a medical emergency and thus requires prompt evaluation and 
initiation of empiric therapy. While a variety of noninfectious causes including transfusion 
of blood products, medications, and the underlying malignancy itself, may cause fever, the 
presence of fever should always be presumed to be due to an underlying infection until 
proven otherwise. Initial evaluation of the neutropenic patient should include a complete 
history, with special attention given to identifying prior chemotherapies, previous infectious 
complications, and recent or current prophylactic antimicrobial therapies. A thorough 
physical examination, blood and bodily fluid cultures -based on clinical suspicion-, and 
appropriate radiographic imaging are integral to the evaluation of these patients.  Clinicians 
should be aware that in the neutropenic host, signs and symptoms of infection may be 
blunted by a decreased inflammatory response and therefore, a high index of clinical 
suspicion is essential for expeditious diagnosis and treatment. For example, only 8% of 
neutropenic patients with pneumonia produce sputum compared to 84% in non neutropenic 
patients (64). 
In order to better stratify which patients require more intensive management, scoring 
systems and treatment algorithms have been devised. For example, the Multinational 
Association for Supportive Care in Cancer (MASCC) scoring system is a well validated tool 
for risk stratification of febrile neutropenic patients based on the burden of illness (mild, 
moderate or severe), absence of hypotension, absence of chronic obstructive lung disease, 
absence of dehydration, age less than 60 years, outpatient status at the time of onset of fever 
and solid tumor or lymphoma with no previous fungal infection (156,157). A cumulative 
score of 20 or more is predictive of a less than 5% chance of developing serious medical 
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complications. This is a valuable tool to identify low risk patients who may be treated as an 
outpatient (158). However, it is more common practice to observe the patient in the hospital 
for at least 24 hours on empiric IV antibiotics to confirm low risk status (159).  
Key points 
 Patients with neutropenic fever should undergo a rapid and comprehensive evaluation. 
 MASCC scoring can be used as a general guide to help risk stratify patients and identify 
those who would benefit from outpatient treatment noting that most leukemia patients 
are high risk and warrant a period of hospitalization.  
1.6. Treatment of infections 
The four basic approaches to infections in leukemia patients include prophylactic 
(prevention of infection in high risk individuals by appropriate medications), empiric 
(initiating treatment on symptomatic individuals before positive cultures), pre-emptive 
(initiating treatment on the basis of positive or rising titers at the onset of clinical or 
radiological signs(160)) and traditional (treatment based on positive cultures). 
During the 1950s it was not common practice to initiate antibacterial therapy before a 
specific pathogen was identified (10). Not surprisingly, this fundamental principle was 
associated with high mortality rate among neutropenic leukemia patients. Early randomized 
trials failed to demonstrate improved outcomes with the use of empiric antibiotics in the 
management of febrile neutropenia (161). However, shortly thereafter, subsequent studies in 
leukemia patients showed a significant benefit for patients treated with empiric antibiotic 
therapy prior to bacteriological data becoming available (162,163). This established the 
paradigm of empiric antibiotic use which is still used to guide the initial approach to 
managing neutropenic leukemia patients. In the setting of neutropenic fever, treatment of 
the most likely focus should be initiated and include coverage for the most virulent and 
prevalent pathogens. In the absence of an obvious focus, broad spectrum empiric therapy 
covering gram positives and gram negatives should be initiated and be guided by 
institutional protocols based on local resistance patterns pending results of initial tests. 
Initial combination therapy should take into consideration any recent antibiotic prophylaxis, 
prior infections including with resistant organisms, presenting signs and symptoms, exam 
findings, severity of infection, organ function, and co-morbidities.     
The three basic antibiotic regimens include: 1) monotherapy with an antipseudomonal beta-
lactam such as cefepime, 2) a beta lactam plus an aminoglycoside or a fluoroquinolone, and 
3) a glycopeptide in addition to beta lactam monotherapy. Due to the concern for emergence 
of resistance, vancomycin is not routinely used in the empiric treatment of neutropenic fever 
unless any of the following criteria are met: positive blood cultures with smears showing 
gram positive cocci, critically ill patients, presence of skin or soft tissue infection, suspicion 
of catheter related infection, or known colonization or prior infection with MRSA (2). 
There are several options for the treatment of MRSA infection.  Vancomycin has been used 
traditionally for this indication. Vancomycin dosing should be adjusted based on trough 
 
Sepsis – An Ongoing and Significant Challenge 348 
levels, with a goal trough of 15-20 mcg/mL.(164) Toxicities associated with high trough 
levels include renal injury, ototoxicity, and myelosuppresison. Vancomycin should not be 
used to treat MRSA infection if the MIC of the MRSA is ≥  2 μg/ml due to a high rate of 
treatment failure (164). Daptomycin has become the second-line agent of choice for MRSA 
infections. Daptomycin can induce eosinophilic pneumonia (165) and has been associated 
with rhabdomyolysis (package insert). Linezolid has the advantage of good bioavailability 
after oral administration, but is bacteriostatic against MRSA and therefore, should be used 
with caution in life-threatening MRSA infections.  Myelosuppression, serotonin syndrome 
when administered concurrently with serotonin uptake inhibitors (SSRI)), and 
rhabdomyolysis are notable linezolid related toxicities (166,167). Ceftaroline is a new 
cephalosporin that has activity against MRSA and is approved for use in skin and soft tissue 
infections (168). Doxycycline, TMP/SMX, and clindamycin all possess activity against most 
MRSA isolates but are traditionally reserved for the treatment of non-life threatening 
infections such as uncomplicated skin and soft tissue infections.  
Even with the initiation of the appropriate empiric antibiotic, it may take days for fevers to 
abate in neutropenic patients; however, if fevers persist without an obvious focus or culture 
result after 4-7days of antibacterial therapy, persistent fever atypical organisms and IFI must 
be considered. In this case, empiric antifungal therapy may be initiated while further 
diagnostic tests are done. Prompt removal of catheters is essential if suspected to be the 
source of infection.  Due to the widespread use of fluconazole and posaconazole as 
antifungal prophylaxis, the possibility of azole resistance should be borne in mind. In the 
treatment of candidemia, IDSA guidelines recommend fluconazole for the less critically ill 
who have not been exposed to this drug or echinocandins, such as micafungin or 
caspofungin (169). Voriconazole or liposomal amphotericin may be used as first line in more 
critically ill individuals. Voriconazole has emerged as a safe and more efficacious alternative 
to liposomal amphotericin for the empiric treatment of fungal infections in febrile 
neutropenia (170) and as the primary therapy of invasive aspergillosis (171) based on two 
landmark randomized trials. The 2008 IDSA guidelines recommend voriconazole as first 
line therapy for invasive aspergillosis (2,74). This drug has high bioavailability in both oral 
and intravenous forms. For patients who fail voriconazole or therapy is limited by toxicity 
such as hallucinations, hepatotoxicity, or skin rash, conventional amphotericin B or 
liposomal preparation can be used (74). Both forms of amphotericin have similar success 
rates but the latter has less toxicity allowing for the use of higher doses. Infusional toxicity 
(fever, chills, and hypotension), potassium and magnesium wasting and frequent renal 
toxicity are complications of amphotericin.  
The three echinocandins in clinical use are caspofungin, micafungin and anidulafungin. This 
class of medications inhibits the synthesis of 1,3-β-D-glucan, an essential component of the 
fungal cell wall (172). All three drugs are fungistatic against Aspergillus spp although the 
minimal effective concentration for micafungin and anidulafungin are 2- 10 fold lower than 
caspofungin (172). Caspofungin has been approved for use in refractory aspergillosis or 
invasive disease where other treatment options cannot be tolerated. It has also been used as 
a single agent in pulmonary aspergillosis in patients with hematological malignancies (173). 
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Micafungin has a clinical efficacy that is comparable to caspofungin (174). Unlike, the other 
echinocandins anidulafungin is unique in that it undergoes elimination by breakdown in the 
bile rather than via hepatic metabolism (172) and like micafungin has the added advantage 
of not requiring dose reduction in moderate liver disease (172). 
Surgical debridement followed by antifungal treatment for zygomycosis (mucormycosis) 
with lipid formulations of amphotericin B is the standard of care (74). Posaconazole is 
recommended as salvage therapy but not as first line (175). Voriconazole is the drug of 
choice in the treatment of scedosporium (176). The optimal duration of therapy in these 
infections has not been determined by clinical trials and is largely determined by the 
treating physician. 
Observational studies have indicated increased mortality with delay in starting antifungal 
therapy (177,178). The dilemma in initiating prompt antifungal therapy is complicated by 
the fact that fewer than 5% patients who receive empiric therapy go on to develop or 
demonstrate evidence of IFI in the first 48 hours (179). Therefore, with the increasing 
availability of newer diagnostic techniques in IFI, there is an interest in active surveillance 
with non-culture based methods and initiation of treatment before the onset of signs and 
symptoms.  This pre-emptive therapy, although being practiced by clinicians, is still 
considered experimental (180) and the NCCN (National Comprehensive Cancer Network) 
does not currently recommend pre- emptive therapy due to lack of sufficient evidence to 
support routine use (181). However, a number of leukemia centers have adopted 
prophylactic and empiric treatment strategies which incorporate anti-fungal therapy. 
Although combination therapy for invasive aspergillosis has shown therapeutic promise in 
a number of small studies (182,183), this approach has not been validated in large 
prospective randomized studies and is not currently recommended.   
In PJP infections, CXR can show bilateral alveolar infiltrates although a normal CXR does 
not exclude the diagnosis. Gold standard for diagnosis is direct immunofluorescence to 
detect the organism although recently measurement of 1-3-beta-d- glucan is being studied 
with interest. So far it has not shown reliable prognostic value and can be elevated in several 
mycoses making it a very non- specific test (184,185). Trimethoprim/ sulfamethoxazole is the 
first line of therapy and is the standard prophylactic agent. Other options include 
pentamidine, trimerexate atovaquone and clindamycin. A high index of suspicion should be 
maintained especially in patients who have received ongoing steroids or T-cell depleting 
therapies. 
Key points: 
 Empiric treatment with broad spectrum coverage in the absence of an obvious focus 
should follow institutional guidelines according to local resistance patterns. 
 Delay in instituting empiric antibiotic and antifungal therapy is associated with worse 
outcomes. 
 One should consider IFI if fever persists > 4-7 days in the setting of appropriate broad 
spectrum antibiotic therapy and negative cultures. 
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 If a source of infection is identified, the therapy should be appropriately tailored/ 
adjusted. 
 Preemptive therapy involves active surveillance to detect viral and fungal infections 
based on rising titers and institution of treatment with onset of symptoms 
 A number of antifungal therapies are available for the treatment of fungal infections in 
leukemia patients and should be selected based on the suspected pathogen, severity of 
illness, and co-morbidities. 
 PJP infection should be suspected in patients with unexplained hypoxia, even in the 
setting of a normal chest xray, especially in patients who have received T-cell depleting 
therapy. 
1.7. Prophylaxis 
Due to the high mortality and costs associated with infections, there is a great interest in 
preventing them. Various approaches have been adopted and this is an area of active 
research. 
Antibiotics: IDSA recommends prophylactic FQ for high risk patients defined as patients 
with expected durations of prolonged and profound neutropenia( ANC ≤ 100 cells/mm3 for 
> 7 days)(2) Among the FQ, ciprofloxacin has maximum activity against Pseudomonas 
whereas levofloxacin has the added advantage of activity against some gram positives and 
once a day dosing at the expense of less anti- pseudomonal coverage(186). The main concern 
with the use of FQ has been the emergence of resistant bacteria. However, surprisingly, in 
the setting of febrile neutropenia, this increase in resistant organisms has not translated into 
increased infectious mortality. (187).(60) 
Antiviral: NCCN recommends acyclovir or valacyclovir for patients with acute leukemia or 
T cell depleting therapy for HSV seropositive individuals throughout the neutropenic phase 
and a minimum of 2 months after alemtuzumab therapy or until the circulating CD4 count 
is more than 0.2 ×109/L (181). Patients who are inactive carriers of hepatitis B virus should 
receive lamivudine 100 mg daily for 3 months following cessation of chemotherapy (181). 
Preemptive influenza chemoprophylaxis with oseltamivir, amantadine or rimantidine is 
recommended after known exposure to a confirmed case during an established outbreak 
(181).  
Antifungals: Outside of bone marrow transplant there is very little evidence to support the 
routine use of antifungal prophylaxis. IDSA recommends prophylaxis against candida 
with fluconazole, itraconazole, voriconazole, posaconazole, micafungin, or caspofungin for 
patients undergoing intensive remission induction or salvage chemotherapy in acute 
leukemia (2). In this group IDSA also recommends use posaconazole for prophylaxis against 
aspergillosis (2). In patients with AML or myelodysplastic syndrome undergoing 
chemotherapy posaconazole prevented IFI compared to fluconazole or itraconazole and was 
associated with improved overall survival (188). NCCN recommends antifungal 
prophylaxis only in leukemia patients receiving mucotoxic regimens including cytarabine 
and anthracycline (181) PJP prophylaxis is recommended for patients receiving 
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alemtuzumab (181) however, many centers have adapted widespread use of PJP 
prophylaxis in patients receiving any T-cell depleting therapy. 
Colony stimulating factors (CSF): The main benefit of CSF is in hastening time to recovery 
of neutrophil function and number of hospital days but these have not been shown to affect 
mortality (189). ASCO guidelines recommend use of CSF in patients at increased risk of 
complications from prolonged neutropenia such as age > 65 yr, poor performance status, 
malnutrition, advanced cancer, bone marrow infiltration, active or open wounds, and/or 
extensive prior treatment (190). Secondary prophylaxis is recommended in individuals who 
experienced complications due to neutropenia during a prior cycle (190). Given the potential 
concern for promotion of myeloid stimulation in active AML, myeloid growth factors are 
typically not given during primary induction therapy. However, they are typically utilized 
in patients after consolidation therapy.  
Intravenous immunoglobulin (IVIG): IVIG is not routinely advised in patients with CLL 
due to lack of known benefit in preventing life threatening infections.  However, it should 
be considered in those with recurrent sinopulmonary infections or in those with underlying 
refractory CLL. In a multicenter double-blind study, 84 CLL patients at high risk for 
infections (history of hypogammaglobulinemia, infections, or both) were randomized to 
receive IV immunoglobulin G (IVIG) (400 mg/kg) every 3 weeks or placebo. Although 
moderate bacterial infections were reduced by 50%, there was no subsequent reduction in 
mortality (191). Another study found that the number of infection related admissions was 
reduced with IVIG administration (192). However in a cost effective analysis it was 
determined that IVIG therapy resulted in a 0.8 day per patient per quality adjusted life year  
at a cost of $6 million per  year gained implying  a prohibitive cost for minimal benefit (193). 
This was mainly due to the loss of quality of life due to the need to receive IV infusion every 
3 weeks. The authors estimated that even if immune globulin were to be given free of cost, 
treatment would result in a net savings of only $814 because of lower infection rates and, 
thus, lower medical costs. At a cost of $50 per treatment, the marginal cost of treatment 
equals that of no treatment (193). 
Active immunization: Annual influenza vaccination is recommended for all cancer patients 
lifelong (2). Immunization responses in CLL patients are variable but suboptimal. One study 
found that 73% of stage zero CLL patients had decreased levels of at least one 
immunoglobulin. Vaccination is most successful if used earlier in the disease, when 
immunoglobulin levels are better preserved, and if protein or conjugated vaccines are used 
(194). Response to hemophilus and tetanus vaccines may be enhanced by the use of adjuvant 
ranitidine but it has no beneficial effect on the response to vaccination with unconjugated 
polysaccharide antigens (195). Given the immunosuppressive effects of leukemia directed 
treatment, it is recommended that vaccines not be performed in the peri-chemotherapy 
period. Live vaccines including polio (oral), typhoid (oral), yellow fever, measles, mumps, 
rubella, BCG and Herpes zoster should not be administered to patients with CLL (18).  
Vaccine based strategies to prevent IFI are hampered by the fact that the population that 
will most benefit from this approach is able to mount the least immune response.. 
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Torosantucci et al have developed a fungal vaccine consisting of laminarin that was 
protective against candidiasis and aspergillosis (196). Currently, developing  vaccines for 
this immunosuppressed patient population remains an active area of research (197).  
Key points 
 Prophylactic antibiotics, antivirals and antifungals should be given to patients at 
highest risk for these infections. 
 The role of IVIG in CLL is controversial and not routinely recommended due to lack of 
cost effectiveness although moderate reduction in infections have been noted and its 
use should be considered in patients with hypogammaglobulinemia and recurrent 
sinopulmonary infections. 
 Patients with CLL should be vaccinated earlier in their disease to reap maximum 
benefit due to decline in antibody response with disease duration. 
 Live virus vaccines should be avoided in immunosuppressed patients. 
 Growth factors shorten the duration of neutropenia but do not impact mortality. 
1.8. Economic burden and outcomes of infections in leukemia  
Infections increase the costs of treatment in patients with leukemia and can drastically 
influence the economic burden of the disease (198). There are no recent direct studies that 
have addressed the economic burden related to infections in patients with leukemia. 
However, in 2000, aggregate US hospital costs were 2.1 billion dollars with AML being the 
most costly leukemia followed by ALL, CML and CLL (198). In patients with CLL, infections 
have been shown to contribute to higher total cost of care (198). Patients with leukemia who 
are critically ill have worse outcomes than non- cancer patients. Relapsed/ refractory status 
of disease and high Sequential Organ Failure Assessment (SOFA) score (a simple and 
objective score that allows for calculation of both the number and the severity of organ 
dysfunction in six organ systems -respiratory, coagulation, liver, cardiovascular, renal, and 
neurologic) (199) have been found to be predictive of high mortality (200). Among ICU 
survivors 1 year mortality for acute leukemia patients is lower than patients with other 
malignancies (201). In a study by Thakkar et al evaluating predictors of outcome for patients 
with acute leukemia admitted to the ICU, respiratory distress was the most frequently 
observed reason for ICU admission or transfer with the majority requiring ventilator 
support (202). The two, six, and twelvemonth overall survival was 24 (27%), 16 (18%), and 
14 (16%), respectively. Higher APACHE II score (a severity of disease classification system 
that helps prognostically risk stratify acutely ill patients) (203), use of vasopressors, 
undergoing bone marrow transplantation preparative regimen, and adverse cytogenetics 
were predictors of worse outcomes whereas a new diagnosis of leukemia, type of leukemia 
and age were not significant. (202). 
A study by Schapira in 1993 evaluated the economic cost of survival in patients with 
hematologic malignancies. Factors noted to be significant for survival included: the  nadir 
platelet count and albumin level prior to and during the ICU stay, the BUN, creatinine, and 
the need for mechanical ventilation. Seventy-eight percent of patients survived less than five 
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months and spent less than two and a half months at home after discharge. Fifty percent of 
patients expired during their ICU stay.  The cost per year of life gained for the entire group 
of patients was $189,339 per.admission (204).  However, this study did not differentiate 
between relapsed/refractory or de novo disease. Documented infection was noted in 54.7% 
of individuals who expired in the hospital. Among patients who were discharged from the 
hospital, documented infections were noted in 29.3% of patients who survived for less than 
6 months but in only 16% of patients who survived for more than 6 months. Taken together, 
these studies highlight the impact of infections in leukemia patients, especially those with 
relapsed/refractory disease, with a direct correlation to hospital mortality and post 
discharge survival (204).  
Careful patient selection improves outcomes without the burden of futile economic costs. It 
has been recommended that patients with good performance status, where life prolonging 
treatment options are available- especially patients with new or recent diagnosis of 
leukemia, should be given the benefit of intensive care support, while patients with poor 
prognosis who may benefit from a palliative care approach should not. This is often a 
difficult choice for the treating provider. A middle of the road approach might be to initiate 
ICU care unless declined by the patient with a goal to regularly reassess the patients wishes 
and/or condition (205) and proceed to comfort care if continued aggressive therapies are 
deemed to be of minimal benefit. 
Key points 
 Intensive care costs for treatment of patients with leukemia are significant 
 Careful selection of patients improves outcomes without adding significantly to 
economic costs. 
 Patients with refractory or relapsed leukemia and poor performance status are unlikely 
to benefit from ICU stay 
 Identifying low risk patients with neutropenia using MASCC scoring can help 
minimize the costs of treatment of neutropenic fever. 
2. Summary 
With rapid advances in diagnostic techniques and availability of newer chemotherapeutic 
and antibiotic medications in the armamentarium against leukemia, the spectrum of 
infections continues to change. Clinicians face evolving clinical, diagnostic and ethical 
challenges to select the most cost effective and evidence based care. The cornerstone of 
therapy should however be an individualized and patient oriented approach in order to 
achieve the best outcomes. 
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